VIRALEZE™ is a nasal spray designed to provide a protective moisture barrier that traps and blocks common viruses in the nose in situations where individuals may be most at risk of developing a respiratory infection.

VIRALEZE™ has been tested in laboratory studies for its effectiveness against a broad spectrum of common respiratory viruses.

Astodrimer sodium in VIRALEZE™ has been shown to trap and block a broad spectrum of respiratory viruses in laboratory studies, including SARS-CoV-2 (the coronavirus that causes COVID-19), MERS-CoV (the coronavirus that causes MERS), SARS-CoV (the coronavirus that causes SARS), H1N1 (the influenza virus that caused Swine Flu), H3N2 (the influenza virus that caused Avian Flu), and RSV (respiratory syncytial virus).

VIRALEZE™ has undergone a clinical trial in the UK with patients diagnosed with COVID-19. The results indicated that VIRALEZE™ significantly reduced SARS-CoV-2 viral load in patients aged 45 years and older compared with a placebo nasal spray. VIRALEZE™ was also shown to increase the rate of COVID-19 viral clearance and helped alleviate some COVID-19 symptoms, especially loss of smell. Although the reduction in viral load was also observed in individuals aged 16 to 45, it was not statistically significant when compared to the placebo.

VIRALEZE™ contains astodrimer sodium, a patented ingredient proven in laboratory studies to trap and block cold and respiratory viruses. The formulation provides a protective moisture barrier in the nose, helping to reduce viral adhesion, multiplication, and spread, allowing your body’s natural defences to remove the viruses.

Astodrimer sodium is a large molecule with multiple negative surface charges. These negative charges serve as sites of engagement with positively charged regions of viral spike proteins and other viral attachment proteins. The electrostatic interaction between astodrimer sodium and the viral attachment proteins is strong due to the polyvalent structure of astodrimer sodium, and is not specific, leading to the ability to block a broad spectrum of respiratory viruses.

VIRALEZE™ can be used up to four times daily. One application is expected to last approximately four hours based on mucociliary clearance time.

Mucociliary clearance is the body’s way of cleaning the airways, which use mucus and tiny hair-like structures in the nose called cilia. Mucus traps dirt, germs, and other particles we breathe in, and the cilia push this mucus up toward the throat, where it can be coughed out or swallowed. This process helps keep our lungs and airways clear, protecting us from infections and pollutants.

To ensure the action of VIRALEZE™ is not affected, we recommend that VIRALEZE™ not be applied immediately before or after other nasal products. If you intend to use VIRALEZE™ with other nasal spray products, we recommend allowing 3-4 hours after applying VIRALEZE™ before applying another product to ensure the barrier function of VIRALEZE™ is not compromised. Consult your healthcare provider for advice if you are using other nasal treatments.